Literature DB >> 19466316

Endoscopic follow-up of cyanoacrylate obliteration of gastric varices.

Fernanda Prata Martins1, Erika Pereira de Macedo, Gustavo Andrade de Paulo, Frank Shigueo Nakao, José Celso Ardengh, Angelo Paulo Ferrari.   

Abstract

Bleeding from gastric varices is a life-threatening condition. We report our experience with cyanoacrylate injection. Twenty three patients with portal hypertension and gastric varices underwent intra-variceal injection of a cyanoacrylate/lipiodol solution (1:1). Study endpoint was variceal obliteration. Mean follow-up was 25.3 months. Variceal obliteration was achieved in 87% of patients. Recurrence occurred in one patient (4.3%) and rebleeding in another case (4.3%). Mild abdominal pain was described in 13% of patients. Overall mortality was 21.7% and rebleeding related mortality rate was 4.3%. Our results confirm that cyanoacrylate injection is effective and safe to eradicate gastric varices.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19466316     DOI: 10.1590/s0004-28032009000100020

Source DB:  PubMed          Journal:  Arq Gastroenterol        ISSN: 0004-2803


  3 in total

1.  Gluing gastric varices in 2012: lessons learnt over 25 years.

Authors:  Vivek A Saraswat; Abhai Verma
Journal:  J Clin Exp Hepatol       Date:  2012-04-12

2.  Efficacy and safety of endoscopic prophylactic treatment with undiluted cyanoacrylate for gastric varices.

Authors:  Matheus Cavalcante Franco; Gustavo Flores Gomes; Frank Shigeo Nakao; Gustavo Andrade de Paulo; Angelo Paulo Ferrari; Ermelindo Della Libera
Journal:  World J Gastrointest Endosc       Date:  2014-06-16

Review 3.  Safety, Efficacy, and Outcomes of N-Butyl Cyanoacrylate Glue Injection through the Endoscopic or Radiologic Route for Variceal Gastrointestinal Bleeding: A Systematic Review and Meta-Analysis.

Authors:  Olivier Chevallier; Kévin Guillen; Pierre-Olivier Comby; Thomas Mouillot; Nicolas Falvo; Marc Bardou; Marco Midulla; Ludwig-Serge Aho-Glélé; Romaric Loffroy
Journal:  J Clin Med       Date:  2021-05-25       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.